drugset / Trial / NCT02852239
Pharmacokinetics of Dabrafenib in Subjects With Renal Impairment
Non-randomizedParallel-groupOpen-labelBasic science
Summary
To characterize the pharmacokinetics and safety of dabrafenib following a single 100 mg oral dose in subjects with severe renal impairment and end stage renal disease not on dialysis.
Timeline
- Start
- 2016-12-19
- Primary completion
- 2019-09-27
- Completion
- 2019-09-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dabrafenib | Small molecule | 100 mg | Oral |